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Objective: A retrospective study involving 13 institutions was performed to assess
the efficacy of conversion from cyclosporine (INN: ciclosporin) to tacrolimus.
Methods: Data from 244 patients were analyzed. Indications for conversion were
recurrent-ongoing rejection (n  110) and stage 1 to 3 bronchiolitis obliterans
syndrome (n  134).
Results: The incidence of acute rejection decreased significantly within 3 months
after versus before the switch from cyclosporine to tacrolimus (P  .01). For
patients with recurrent-ongoing rejection, the forced expiratory volume in 1 second
decreased by 1.96% of predicted value per month (P .08 vs zero slope) before and
increased by 0.34% of predicted value per month (P  .32 vs zero slope) after
conversion (P  .06). For patients with stage 1 to 3 bronchiolitis obliterans
syndrome, a significant reduction of rejection episodes was observed (P  .01). In
single transplant recipients a decrease of the forced expiratory volume in 1 second
averaged 2.25% of predicted value per month (P  .01 vs zero slope) before and
0.29% of predicted value per month after conversion. Corresponding values for
bilateral transplant recipients were 3.7% of predicted value per month (P  .01 vs
zero slope) and 0.9% of predicted value per month (P  0.04 vs zero slope),
respectively. No significant difference in the incidence of infections within 3 months
before and after conversion was observed.
Conclusions: Conversion from cyclosporine to tacrolimus after lung transplantation
is associated with reversal of recurrent-ongoing rejection. Conversion for bronchi-
olitis obliterans syndrome allows short-term stabilization of lung function in most
patients.
Short-term outcome after lung transplantation has improved signifi-cantly over the last decade, but long-term survival remains limited bythe development of bronchiolitis obliterans syndrome (BOS),1-3which is believed to be a manifestation of chronic allograft rejectionand occurs in as much as 30% to 50% of patients at 2 years aftertransplantation. Clinical reports have demonstrated that acute rejec-
tion (AR), especially when histologically severe or refractory to treatment, is the
primary risk factor for BOS.1-8 Tacrolimus, which is a more potent immunosup-
pressive agent than cyclosporine (INN: ciclosporin) in vitro,9 has been successfully
used in the treatment of intractable acute and chronic rejection after kidney,10
liver,11 and heart12 transplantation. After these reports, several studies have assessed
tacrolimus as rescue therapy for recurrent-ongoing acute and chronic rejection after
lung transplantation. They suggested that conversion from cyclosporine to tacroli-
mus significantly reduces the incidence and severity of AR13-17 and might stabilize
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pulmonary function in patients with BOS.15,18-20 These re-
sults, however, are difficult to interpret because they come
from single-center studies that included small numbers of
patients (ie, between 10 and 15) and did not allow stratifi-
cation according to the indication for conversion or type of
transplant procedure. To overcome these limitations, we
undertook this retrospective multicenter study to assess the
effects of conversion from cyclosporine to tacrolimus on
recurrent-ongoing acute rejection (RAR) and BOS in a
larger cohort of lung transplant recipients.
Methods
Patients
Data from 13 European, Australian, and Canadian lung transplan-
tation centers were collected by means of questionnaire. Each
center was asked for clinical data of all patients ever converted
from cyclosporine to tacrolimus for RAR, BOS, or both up to
December 2000. Data included (1) patient’s age and sex; (2)
indication for transplantation, type of transplantation, and time
from transplantation to conversion; (3) duration of follow-up and
outcome; (4) immunosuppression at the time of conversion; (5)
incidence of episodes of AR within 3 months before and 3 months
after conversion; (6) values of forced expiratory volume in 1
second (FEV1) at 3 and 6 months before conversion, at the time of
conversion, and at 3, 6, and 12 months after conversion; and (7)
incidence of infectious complications and values of serum creati-
nine within 3 months before and 3 months after conversion.
Patients were grouped according to the indication for conver-
sion. Group 1 (RAR) included patients who were switched from
cyclosporine to tacrolimus for RAR, which was defined as 2 or
more episodes of rejection within 3 months before conversion, as
diagnosed on the basis histology (A1) or clinical changes (eg, a
decrease in lung function or a change in chest radiographic results
that responded to augmented immunosuppression and was not
explained by other causes), and patients who were switched for
refractory (ongoing) AR (defined by A1 histologic changes on
consecutive sets of biopsies). Group 2 (BOS) included patients
who had BOS of greater than stage 0, as defined by the Interna-
tional Society for Heart and Lung Transplantation.21 This classi-
fication indicates that a patient with an FEV1 value of between
100% and 81% of the best postoperative value is in BOS stage 0;
corresponding FEV1 values for BOS stages 1, 2, and 3 are 66% to
80%, 51% to 65%, and 50% or less of baseline values, respec-
tively. Conversion of cyclosporine to tacrolimus was also per-
formed at some centers for patients who showed a decrease in
FEV1 of less than 19% compared with the baseline value, a
decrease in the midexpiratory flow rate, or both; these patients
were categorized as being in pre-BOS, stage, and their data were
not analyzed in this study.
Patients with a combination of RAR and BOS were allocated to
the BOS group. For analysis of procedure-related results, patients
were divided into recipients of single lung transplantation (SLT)
and bilateral lung transplantation (BLT). Patients with combined
heart-lung transplantation were included in the BLT group. Data
for patients who underwent retransplantation were only included
for the period preceding the second procedure.
Statistical Analysis
Continuous variables are reported in the text as means  SD. The
SAS system was used for calculation.22
Changes in FEV1 values. Statistical analysis of changes in
FEV1 values (expressed as percent predicted) before and after
conversion was performed by means of change-point regression
analysis with a mixed linear model (SAS Proc Mixed). Slopes
before and after conversion were estimated separately for recipi-
ents of SLT and BLT and were compared with the zero slope.22
The mixed-model analysis was performed separately for the RAR
and stage 1 to 3 BOS (BOS1-3) groups. For the RAR group, data
were fitted for the 3-month period before conversion and for the
12-month period after conversion. For the BOS groups, data were
fitted for the 6-month period before and the 12-month period after
conversion. All available FEV1 values within the specified periods
were included in the analysis.
AR episodes. The significance of differences in the total num-
ber of AR episodes within 3 months before and 3 months after
conversion were assessed by using the Wilcoxon signed-rank test.
For other parameters, the Student t test or Wilcoxon signed-rank
test was used.
Results
Patients and Immunosuppression
Data from 280 patients were collected from 13 centers. The
patients in the pre-BOS stage were excluded from the study
(n  26). Ten patients with incomplete data or retransplan-
tation within 2 months before conversion were excluded
from the final analysis. The study thus included 244 pa-
tients, of whom 30% underwent SLT, 52% underwent BLT,
and 18% underwent heart-lung transplantation. Ten patients
underwent retransplantation after the switch. Retransplanta-
tion was performed at least later than 3 months after the
conversion in all 10 patients. The patients were 38  14
years (mean  SD) of age and included 141 male and 103
female subjects. Indications for transplantation were
chronic obstructive pulmonary disease–emphysema (19%),
cystic fibrosis (29%), primary pulmonary hypertension
(10%), idiopathic pulmonary fibrosis (15%), and a variety
of other diseases (27%).
The RAR group included 110 patients in whom 229
episodes of rejection were diagnosed either on the basis of
histology (63%) or clinically (37%) during the 3-month
period before conversion. Within the 3-month period after
conversion, 28 episodes of rejection were diagnosed either
on the basis of histology (64.3%) or clinically (35.7%). The
BOS group included 160 patients, of whom 26 (16%) were
in the pre-BOS stage and 134 (84%) were in BOS stages 1
to 3 at the time of conversion (49 in BOS stage 1, 53 in BOS
stage 2, and 32 in BOS stage 3). In the BOS1-3 group 60
patients experienced a total of 83 episodes (18% of which
were proved by means of biopsy) during the 3-month period
before conversion. Within the 3-month period after conver-
sion, a total of 17 episodes of rejection (6% proved by
means of biopsy and 94% clinically diagnosed) were de-
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tected in the BOS1-3 group. Median time from transplan-
tation to conversion was 4.0 months (range, 0.5-76 months)
for the RAR group and 29.3 months (range, 2.3-105
months) for the BOS group (P  .01). Median observation
time after conversion was 16.1 months (range, 0.7-91.3
months) for the RAR group and 18.4 months (range, 0.1-
69.1 months) for the BOS group (P  .58).
In addition to cyclosporine and steroids, 63 patients in
the RAR group received azathioprine and 24 patients re-
ceived mycophenolate mofetil at the time of conversion.
Twenty-three patients received another immunosuppressive
medication (eg, methotrexate or cyclophosphamide). In the
BOS group 73 patients received azathioprine, 42 patients
received mycophenolate mofetil, and 45 patients received
another medication. As a whole, 168 patients in this study
had received one or more courses of cytolytic therapy
(antithymocyte globulin [ATG], 99%, or antilymphocyte
globulin [ALG], 1%).
Fourteen patients in the RAR group received ATG (n 
9) or OKT3 (n  5) within the last 3 months before
conversion as rescue therapy. In the BOS group 19 patients
received cytolytic therapy (ATG, n  8; OKT3, n  4;
RAT, n  6; and ATG  OKT3, n  1) within 3 months
before conversion.
Effect of Conversion in the RAR Group
Incidence of rejection. Data on the incidence of rejec-
tion are shown in Tables 1 and 2. The incidence of histo-
logically proved and clinically diagnosed episodes of AR
decreased significantly during the 3-month period after ver-
sus before the switch from cyclosporine to tacrolimus (P 
.01). This paralleled a reduction in the number of steroid
pulses (data not shown). In 7 patients the number of epi-
sodes of AR decreased by 4 after the switch, in 18 patients
it decreased by 3, in 42 patients it decreased by 2, and in 34
patients it decreased by 1. In 6 patients there was no change
in the number of AR episodes, and in 1 patient the number
increased by 1 after the conversion.
Change in FEV1 values. The top panel of Figure 1
shows that, on average, FEV1 values tended to decrease
before conversion and to increase after conversion. Neither
the preconversion slope nor the postconversion slope was
significantly different from the zero slope (Figure 1, lower
panel), but the change in slope between the 2 periods almost
reached statistical significance (P  .06). At 1 year after
conversion, 67.6% of the 71 patients for whom functional
data were available were still in BOS stage 0, but 16.9% had
progressed to BOS stage 1, 9.9% to BOS stage 2, and 5.6%
to BOS stage 3.
Effect of Conversion in the BOS1-3 Group
Incidence of rejection. Data on the incidence of rejec-
tion are shown in Tables 1 and 2. Similar to the observation
made in the RAR group, conversion to tacrolimus produced
a significant reduction in the mean number of histologically
proved and clinically diagnosed rejection episodes. Of the
60 patients who had AR before conversion, in 1 patient the
number of episodes decreased by 4, in 1 patient by 3, in 12
patients by 2, and in 37 patients by 1 when the 3-month
periods before and after conversion were compared. In 5
patients there was no change in the number of AR episodes,
and in 4 patients this number increased by 1.
Change in FEV1 values. The top panel in Figure 2
shows that FEV1 values decreased substantially before con-
version. Conversion from cyclosporine to tacrolimus had a
dramatic effect, with a marked reduction in the rate of FEV1
decrease. On average, the rate of change in FEV1 values in
the BLT recipients averaged 3.7% of the predicted value
per month before (P  .01) and 0.9% of the predicted
value per month after conversion (P  .01); corresponding
values for SLT recipients were 2.5% of predicted value
per month (P  .01) and 0.3% of predicted value per
month, respectively. The change in slope after the conver-
sion was significant (P  .01) in both BLT and SLT
recipients and was observed in each of the 3 BOS groups.
Infections and Renal Function
The incidence of cytomegalovirus and noncytomegalovirus
viral infections, bacterial infections, and fungal infections,
as well as the total number of infectious episodes, was not
significantly different for the 3-month period before and
after conversion. Comparison of mean serum creatinine
levels obtained during these 2 periods showed a significant
increase after conversion. In the RAR group mean serum
creatinine values increased from 1.3  0.9 mg/100 mL to
1.5  1.2 mg/100 mL (P  .01); corresponding values in
patients converted for BOS were 1.5  0.7 mg/100 mL and
1.7  0.9 mg/100 mL, respectively (P  .04).
TABLE 1. Mean number of histologic and clinical episodes of acute rejection in 242 patients during a 3-month period
before and after conversion from cyclosporine to tacrolimus
RAR BOS1–3
Before After P value Before After P value
Histologic rejection 1.3 1.1 (67.9%) 0.2 0.4 (64.3%) .01 0.1 0.4 (18%) 0.007 0.08 (6%) .01
Clinical rejection 0.8 1.0 (32.1%) 0.1 0.3 (35.7%) .01 0.5 0.7 (82%) 0.1 0.3 (94%) .01
Data for 2 patients in the RAR group are missing. RAR, Recurrent-ongoing acute rejection; BOS, bronchiolitis obliterans syndrome.
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Discussion
Despite intense immunosuppression, acute allograft rejec-
tion is still common after lung transplantation.1,2 This sus-
ceptibility has been attributed to the fact that unlike other
solid-organ transplants, the lung is constantly exposed to
inhaled agents, such as antigens, toxins, irritants, and exog-
enous infectious agents, which promote local inflammation
and might increase expression of HLA antigens. In addition,
a substantial mass of lymphoid tissue containing large
amounts of immune effector cells is transplanted with the
graft. The Registry of the International Society for Heart
and Lung Transplantation3 indicates that approximately
40% of adult and pediatric lung transplant recipients are
currently treated with cyclosporine-based triple-drug immu-
nosuppression. This regimen is effective to avoid lethal AR,
but it is not powerful enough to prevent mild-to-moderate
(ie, grades 2 and 3) AR. Furthermore, in a substantial
proportion of patients, AR might persist or recur after an
TABLE 2. Frequency table for the differences of the total number of rejections (clinical and histologic) per patient 3 months
before and 3 months after conversion from cyclosporine to tacrolimus
4 episodes 3 episodes 2 episodes 1 episode Unchanged 1 episode
RAR 7 18 42 34 6 1
BOS1–3 1 1 12 37 74 4
RAR, Recurrent-ongoing acute rejection; BOS, bronchiolitis obliterans syndrome.
Figure 1. Upper panel, change in mean FEV1 (expressed as percent predicted) values over time in patients with
RAR. Figures indicate numbers of patients for whom data were available at each time point. Bars  1 SEM.
Lower panel, Rate of decrease of FEV1 value before and after conversion.
Sarahrudi et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 4 1129
G
TS
initial response to treatment with high-dose methylpred-
nisolone. In 2 previous reports17,23 more than one third of
all lung transplant recipients studied had RAR. Because
more frequent, long-lasting, and severe episodes of AR are
the primary risk factor for BOS,1-8 it is critical to develop
immunosuppressive strategies that provide a better control
of RAR than cyclosporine and corticosteroids.
Two strategies have been used to control RAR. The first
is to intensify immunosuppression by adding a course of
cytolytic therapy,24 methotrexate,25 photopheresis,26 total
lymphoid irradiation,27 or aerosolized cyclosporine28 to the
maintenance regimen (Table 3). The second approach is to
modify the maintenance immunosuppression, for example
by substituting tacrolimus for cyclosporine or mycopheno-
late mofetil for azathioprine. Because the available infor-
mation on the efficacy of a switch from cyclosporine to
tacrolimus was based on single-center reports involving
small numbers of patients, we undertook this retrospective
study that included data from 110 patients with RAR. Our
results indicate that conversion to tacrolimus resulted in a
remarkable reduction in the number of rejection episodes,
irrespective of whether AR was diagnosed on the basis of
histology or clinically, and in the number of pulse-steroid
therapies. Overall, 94% of patients in the RAR group ex-
perienced a decrease in the number of rejection episodes,
and AR was documented in only 22% of the patients after
conversion from cyclosporine to tacrolimus. In addition,
conversion also markedly decreased the incidence of AR in
patients with BOS.
These data confirm and extend 5 previous encouraging
reports on the efficacy of tacrolimus in the treatment of
RAR.13-17 Three of these reports included more than 10
patients. In the report on the randomized prospective trial of
cyclosporine-based versus tacrolimus-based maintenance
Figure 2. Data for patients in the BOS1-3 group shown in the same format as in Figure 1; the slope analysis is
performed separately for SLT and BLT recipients.
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immunosuppression, Griffith and colleagues13 reported on
13 patients who were converted from cyclosporine to ta-
crolimus for uncontrollable multiple episodes of AR; RAR
resolved in 8 patients and improved in 2. The study from the
St Louis group,16 which included 14 patients with biopsy-
proved AR, showed that changeover from cyclosporine to
tacrolimus resulted in a marked decrease in the number of
episodes of rejection per patient and per patient-day and in
the average histologic grade of rejection. Similarly, the
study by Onsager and associates17 from Wisconsin showed
reversal of biopsy-proved AR in 8 patients and stabilization
of FEV1 in 3 additional patients after conversion, whereas 4
patients did not respond to tacrolimus rescue therapy. The
efficacy of tacrolimus in controlling RAR is in keeping with
the observation that, when used as a primary immunosup-
pressive agent in solid-organ transplantation, including
lung13,29,30 transplantation, tacrolimus is associated with a
lower incidence of AR compared with cyclosporine.
The observation that conversion to tacrolimus provided
an effective control of RAR in most patients does not imply,
however, that it might prevent the later development of
BOS. In the present study 32% of the 71 patients for whom
functional data were available had BOS stage greater than 0
at 1 year after conversion. This was observed in only 1 of
the 14 patients studied by Horning and coworkers16 but in
10 of the 15 patients studied by Onsager and associates.17
This different incidence of BOS cannot be accounted for by
differences in the duration of follow-up after conversion
because it was very similar in the 3 studies (16.1 months in
the present study, 15.0 months in the study by Horning and
coworkers16, and 17.1 months in the study by Onsager and
associates17). Such a relatively short follow-up, however,
does not enable one to draw any valid conclusion on the
efficacy of a switch from cyclosporine to tacrolimus in the
prevention of BOS.
Three previous studies have assessed the effect of con-
version from cyclosporine to tacrolimus in patients with
established BOS.18-20 These studies included a total of 33
patients, of whom 30% were in BOS stage 1, 30% were in
BOS stage 2, and 40% were in BOS stage 3. In each study
conversion from cyclosporine to tacrolimus significantly
decreased the monthly rate of decrease in FEV1, which
ranged from 69 to 160 mL/mo before the switch and
from 24 to 30 mL/mo after the switch. The present data
show that these gratifying results are confirmed when a
much larger group of patients is studied. The beneficial
effect of the conversion on lung function was observed in
each BOS group, with stabilization of FEV1 values, and in
both SLT and BLT recipients (Figure 2).
As in previous studies,16,17 no major adverse effects of
tacrolimus treatment were encountered. The incidence of
infections did not increase after conversion. The slight in-
crease in serum creatinine values in the 3-month period after
conversion might be related to the nephrotoxicity of tacroli-
mus, in particular when trough levels are in the upper
portion of the therapeutic range. Alternatively, it might
reflect progression of an already established impairment of
kidney function because of the previous use of cyclosporine.
The present study is limited by its retrospective design,
the number of missing data, and the absence of a control
group. Because the risk of rejection decreases with time
after the operation, we cannot exclude that the reduced
incidence of AR after conversion to tacrolimus was coinci-
dental.
We also cannot exclude that the beneficial effect that is
attributed to the conversion from cyclosporine to tacrolimus
might represent the collective effect of the change in cal-
cineurin inhibitor plus other contemporaneous interven-
tions.
Similarly, because the rate of loss of lung function in
many obstructive lung diseases is nonlinear, with the rate of
decrease in FEV1 decreasing as airflow obstruction becomes
more severe, the possibility exists that the stabilization of
lung function observed in patients with BOS after conver-
sion might have been observed without changing medica-
tions. However, the fact that the beneficial effects of con-
version were robustly observed in a large group of patients
makes a cause-effect relationship plausible. Thus the
present findings should be interpreted as suggestive that
conversion from cyclosporine to tacrolimus is associated
with reversal of RAR and with slowing of functional loss in
most patients with established BOS. These results should
now be further corroborated by a prospective randomized
trial in a large number of lung transplant recipients before
advocacy of widespread tacrolimus prescription for control
of RAR and BOS.
We acknowledge the contributions from S. Keeshavjee,
C. Aboyoun, Greg I. Snell, J. Wardle, and H. Treede. We
thank Fujisawa Company for supporting the collection of
data.
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